Literature DB >> 24694533

Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.

Y Inaguma1, Y Akahori2, Y Murayama1, K Shiraishi3, S Tsuzuki-Iba1, A Endoh1, J Tsujikawa1, A Demachi-Okamura3, K Hiramatsu3, H Saji4, Y Yamamoto1, N Yamamoto5, Y Nishimura6, T Takahashi3, K Kuzushima3, N Emi1, Y Akatsuka7.   

Abstract

The genetic transfer of T-cell receptors (TCRs) directed toward target antigens into T lymphocytes has been used to generate antitumor T cells efficiently without the need for the in vitro induction and expansion of T cells with cognate specificity. Alternatively, T cells have been gene-modified with a TCR-like antibody or chimeric antigen receptor (CAR). We show that immunization of HLA-A2 transgenic mice with tetramerized recombinant HLA-A2 incorporating HA-1 H minor histocompatibility antigen (mHag) peptides and β2-microglobulin (HA-1 H/HLA-A2) generate highly specific antibodies. One single-chain variable region moiety (scFv) antibody, #131, demonstrated high affinity (KD=14.9 nM) for the HA-1 H/HLA-A2 complex. Primary human T cells transduced with #131 scFV coupled to CD28 transmembrane and CD3ζ domains were stained with HA-1 H/HLA-A2 tetramers slightly more intensely than a cytotoxic T lymphocyte (CTL) clone specific for endogenously HLA-A2- and HA-1 H-positive cells. Although #131 scFv CAR-T cells required >100-fold higher antigen density to exert cytotoxicity compared with the cognate CTL clone, they could produce inflammatory cytokines against cells expressing HLA-A2 and HA-1 H transgenes. These data implicate that T cells with high-affinity antigen receptors reduce the ability to lyse targets with low-density peptide/MHC complexes (~100 per cell), while they could respond at cytokine production level.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24694533     DOI: 10.1038/gt.2014.30

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  27 in total

1.  Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.

Authors:  Christopher J Holland; Rory M Crean; Johanne M Pentier; Ben de Wet; Angharad Lloyd; Velupillai Srikannathasan; Nikolai Lissin; Katy A Lloyd; Thomas H Blicher; Paul J Conroy; Miriam Hock; Robert J Pengelly; Thomas E Spinner; Brian Cameron; Elizabeth A Potter; Anitha Jeyanthan; Peter E Molloy; Malkit Sami; Milos Aleksic; Nathaniel Liddy; Ross A Robinson; Stephen Harper; Marco Lepore; Chris R Pudney; Marc W van der Kamp; Pierre J Rizkallah; Bent K Jakobsen; Annelise Vuidepot; David K Cole
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

2.  Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.

Authors:  D P Granados; A Rodenbrock; J-P Laverdure; C Côté; O Caron-Lizotte; C Carli; H Pearson; V Janelle; C Durette; E Bonneil; D C Roy; J-S Delisle; S Lemieux; P Thibault; C Perreault
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

Review 3.  Therapeutic T cell engineering.

Authors:  Michel Sadelain; Isabelle Rivière; Stanley Riddell
Journal:  Nature       Date:  2017-05-24       Impact factor: 49.962

Review 4.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 5.  Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.

Authors:  Hiroki Torikai; Laurence Jn Cooper
Journal:  Mol Ther       Date:  2016-05-16       Impact factor: 11.454

Review 6.  Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.

Authors:  Conrad R Y Cruz; Catherine M Bollard
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

7.  Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

Authors:  Yasushi Akahori; Linan Wang; Motohiro Yoneyama; Naohiro Seo; Satoshi Okumura; Yoshihiro Miyahara; Yasunori Amaishi; Sachiko Okamoto; Junichi Mineno; Hiroaki Ikeda; Takehiro Maki; Hiroshi Fujiwara; Yoshiki Akatsuka; Takuma Kato; Hiroshi Shiku
Journal:  Blood       Date:  2018-07-25       Impact factor: 22.113

Review 8.  Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Authors:  R Oostvogels; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

Review 9.  TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential.

Authors:  Mansour Poorebrahim; Niloufar Mohammadkhani; Reza Mahmoudi; Monireh Gholizadeh; Elham Fakhr; Angel Cid-Arregui
Journal:  Cancer Gene Ther       Date:  2021-03-02       Impact factor: 5.987

10.  Single Molecule Force Spectroscopy Reveals Distinctions in Key Biophysical Parameters of αβ T-Cell Receptors Compared with Chimeric Antigen Receptors Directed at the Same Ligand.

Authors:  Debasis Banik; Maryam Hamidinia; Joanna Brzostek; Ling Wu; Hannah M Stephens; Paul A MacAry; Ellis L Reinherz; Nicholas R J Gascoigne; Matthew J Lang
Journal:  J Phys Chem Lett       Date:  2021-08-04       Impact factor: 6.888

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.